Thursday, 15 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 4, 2026

Ladder Capital's Asset Management Head Sells 35,000 Shares — What's Really at Stake?

View original at finance.yahoo.com
Ladder Capital's Asset Management Head Sells 35,000 Shares — What's Really at Stake? On May 29 and June 2, 2026, Robert Perelman, Head of Asset Management at Ladder Capital Corp (NYSE:LADR), reported the open-market sale of 35,000 shares of Common Stock, according to a SEC Form 4 filing…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Over the past two years, Perelman executed two open-market sales totaling 60,000 shares; the 35,000-share transaction is his largest individual direct sale in that period, with the prior sale involving 25,000 shares.

    60% confidence

  • This transaction accounted for 7.55% of Perelman's direct Common Stock position, reducing his direct holdings from 463,684 to 428,684 shares.

    60% confidence

  • No indirect holdings or derivative securities were involved; all shares sold were held directly, with no involvement from trusts, LLCs, or derivative securities.

    60% confidence

  • Perelman continues to hold 428,684 shares of Common Stock directly, supporting a continuing alignment with shareholders.

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
Ladder Capital's Asset Management Head Sells 35,000 Shares — What's Really at Stake? — Source | Via News | ViaNews EU